D.E. Shaw & Co
PRME icon

D.E. Shaw & Co’s Prime Medicine PRME Stock Holding History

D.E. Shaw & Co’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Sell
648,940
-744,681
-53% -$2.47M ﹤0.01% 3051
2026
Q1 		$4.85M Sell
1,393,621
-157,748
-10% -$600K ﹤0.01% 2201
2025
Q4 		$5.38M Sell
1,551,369
-664,483
-30% -$2.96M ﹤0.01% 2239
2025
Q3 		$12.3M Buy
+2,215,852
New +$9M 0.01% 1525
2024
Q4 		– Sell
-139,451
Closed -$540K – 4771
2024
Q3 		$540K Buy
139,451
+94,016
+207% +$436K ﹤0.01% 3653
2024
Q2 		$234K Buy
45,435
+18,767
+70% +$114K ﹤0.01% 4015
2024
Q1 		$187K Buy
+26,668
New +$202K ﹤0.01% 3936

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

D.E. Shaw & Co's PRME Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Prime Medicine (PRME) stake by 53% in Q2 2026, selling an estimated $2.47M and leaving 648,940 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3051.

D.E. Shaw & Co first reported a position in PRME in Q1 2024 and has held it in 7 quarters since. The position peaked at $12.3M in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • D.E. Shaw & Co held 648,940 shares of Prime Medicine worth $2.39M as of Q2 2026.
  • D.E. Shaw & Co sold 744,681 Prime Medicine shares in Q2 2026, an estimated $2.47M.
  • Prime Medicine made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3051 holding.
  • D.E. Shaw & Co first reported a position in Prime Medicine in Q1 2024 and has held it in 7 quarters since.
  • D.E. Shaw & Co's Prime Medicine position peaked at $12.3M in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.